The hottest Biotech Substack posts right now

And their main takeaways
Category
Top Business Topics

Who's Who in A.I.

Gradient Ascendant • 18 implied HN points • 01 Mar 23
🕹 Technology Biotech
  1. OpenAI is a major player in the AI industry, led by controversial figures like Elon Musk.
  2. Microsoft has made a comeback in the AI field through partnerships and investments, notably with OpenAI.
  3. An increasingly vibrant AI ecosystem is emerging with startups, enthusiasts, and established companies all contributing to the field.

Axial Daily #1 (Biotech Exits)

axialdaily • 2 HN points • 17 Mar 23
💼 Business Biotech
  1. Important theme in biotech exits: Selling to large companies like Sanofi early on can be valuable.
  2. On average, biotech companies took about 13.8 years from founding to exit, with a valuation of $5.6B at acquisition.
  3. Success stories in biotech highlight the value of innovative technologies and focusing on unmet medical needs.

Unpaywalled: Globo Homo Economicus

Reactionary Feminist • 3 implied HN points • 25 Oct 24
🎭️ Culture Biotech
  1. Replacism is an ideology that looks beyond just changes in demographics. It also connects to broader ideas like transhumanism and biotechnology.
  2. Renaud Camus has a significant viewpoint on the concept of replacism, suggesting it impacts our understanding of identity and existence.
  3. The discussion around replacism invites people to think about how technology and society might change our bodies and identities in the future.

Free money, who doesn't like free money?

Klement on Investing • 1 implied HN point • 13 Feb 24
💰 Finance Biotech
  1. Who doesn't like free money? A post discussing the appeal of free money and investment ideas on a podcast.
  2. European equity markets and investment opportunities in the UK are topics discussed in the podcast.
  3. The episode mentioned trashing Cassandras and doom-mongers, advocating for growth investment ideas.
Get a weekly roundup of the best Substack posts, by hacker news affinity:

Biotech Basics: Avoiding Common Pitfalls

Boutique Biotech • 0 implied HN points • 15 Jun 23
💰 Finance Biotech
  1. Biotech stock trading down after announcing 'successful results' could indicate data not being truly successful.
  2. Companies may highlight cherry-picked positive results, while the overall study did not meet expectations.
  3. It's important to be cautious when biotech companies start discussing specific parts of their studies.

Gossamer Bio in the spotlight

Boutique Biotech • 0 implied HN points • 21 Jun 23
💰 Finance Biotech
  1. Gossamer Bio's stock fell in December 2022 after Phase 2 data release.
  2. GOSS performed well in 'sicker' Class III PAH patients but not as well in 'less sick' Class II patients.
  3. The post discusses a deep dive into the value and outlook of Gossamer Bio.

💥New Chapter 11 Bankruptcy - NanoString Technologies Inc. ($NSTG)💥

PETITION • 0 implied HN points • 11 Feb 24
💰 Finance Biotech
  1. NanoString Technologies Inc. filed for Chapter 11 bankruptcy due to patent litigation, seeking a buyer.
  2. NanoString is a biotech company supplying technologies for analyzing biological samples in pharmaceutical product development.
  3. NanoString has a significant customer base including academic and government research facilities, biopharma companies, and clinical laboratories.

Y-Combinator’s 2024 RFS - Analyzing the Fastest Growing Companies Across Ep 2

Golden Pineapple • 0 implied HN points • 29 Feb 24
💼 Business Biotech
  1. A top priority across various sectors is bringing manufacturing back to America, with bipartisan support and significant government investments.
  2. SpaceX has shown the effectiveness of private space companies, with companies like Anduril proving the same in the defense technology sector.
  3. Foundational models for biological systems and stablecoin finance are seeing significant growth, with companies like Science and Ava Labs leading the way.

Izon

ASeq Newsletter • 0 implied HN points • 26 Aug 25
🕹 Technology Biotech
  1. Izon has a unique machine for measuring particle sizes that goes beyond just measuring current, which provides more detailed information.
  2. The company can change the size of tiny openings in their device, allowing them to analyze particles that are much smaller than what other machines can handle.
  3. Despite having been around for a while and seeing some funding during COVID, Izon hasn't yet revealed major breakthroughs, but their technology has the potential for more exciting uses in the future.

20251130

Curious futures (KGhosh) • 0 implied HN points • 30 Nov 25
🕹 Technology Biotech
  1. Technology and AI are reshaping work and everyday life quickly, from AI tools that help developers and job seekers to new hardware like robotaxis and advanced chips.
  2. Security risks are rising across cyber and physical spaces, with drones, undersea vehicles, hacking, and foreign influence operations creating fresh vulnerabilities.
  3. These innovations carry human costs and trade-offs — growing antibiotic resistance, erosion of authentic human voice, job disruption, and nostalgia that can distract from real risks.

The Nucleus Genomics Drama

ASeq Newsletter • 0 implied HN points • 04 Dec 25
💼 Business Biotech
  1. A prominent investor associated with Nucleus Genomics made a Nazi salute in public, creating a major reputational issue for the company.
  2. Multiple posts allege problems with Nucleus's legitimacy and integrity, and the company's aggressive response appeared to make things worse.
  3. The critic behind the allegations is controversial and shares risky health advice, but their claims still raise important concerns people should consider.

SemiConBio - Roswell Reboot

ASeq Newsletter • 0 implied HN points • 28 Nov 25
🕹 Technology Biotech
  1. The old Roswell company appears to be rebooting as SemiConBio with a new CEO (Mike Aicher) and a small team still active, which is surprising given expectations they were out of cash.
  2. Recent successful demonstrations of DNA expansion by companies like Roche could lower the technical bar for solid‑state readout technologies, making such sensors more attractive as alternatives to bilayer nanopores.
  3. SemiConBio’s specific sequencing approach probably isn’t a direct fit for reading expanded DNA, but some of its components or techniques might be repurposed to build a high‑speed, solid‑state readout.

QuantumDx

ASeq Newsletter • 0 implied HN points • 10 Feb 26
🕹 Technology Biotech
  1. QuantumDx has shifted from researching FET nanowire DNA sequencing to developing sample-to-answer qPCR platforms.
  2. This represents a big technological pivot toward a more conservative, near-term, market-ready diagnostics strategy instead of experimental sequencing hardware.
  3. The latest update about the company is published as paid, subscriber-only content.

10 Charts That Capture How the World Is Changing

Digital Native • 0 implied HN points • 25 Feb 26
🕹 Technology Biotech
  1. AI is still in the very early innings worldwide, but user engagement and time spent on AI apps are rising fast and could steal attention from other media. Usage is concentrated now (mostly free users and developers), yet agent calls and broader adoption promise bigger workplace and consumer shifts over time.
  2. Healthcare is the largest driver of job growth and will keep creating many new roles as the population ages, telehealth expands, and AI tackles administrative work. Peptides — especially new drugs like retatrutide — are a booming consumer and therapeutic market with huge commercial potential.
  3. Market structures and behaviors are changing: secondaries are becoming a major exit path that speeds liquidity for founders and employees, while prediction markets and viral essays fuel speculation and volatility. That makes exits and returns more flexible but also turns markets more meme-driven and sensitive to narrative shocks.

Biotech Week in Review | 03-03-2023

Engineering the Future • 0 implied HN points • 05 Mar 23
🔬 Science Biotech
  1. Viz.ai receives support for cardiomyopathy-spotting AI using ECG and ML for patient conditions
  2. Big Pharma saw recovery in 2022 shifting focus from biotechs, providing stability and risk aversion
  3. Chan Zuckerberg Initiative expanding to Chicago biohub emphasizing precision data for biotech advancements